Literature DB >> 9156246

Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation.

D Körholz1, D Kunst, L Hempel, D Söhngen, A Heyll, H Bönig, U Göbel, F Zintl, S Burdach.   

Abstract

Ex vivo production of interleukin 10 (IL-10) and interferon-gamma (IFN-gamma) was investigated in patients with (n = 5) or without (n = 5) chronic graft-versus-host disease (cGVHD) after allogeneic BMT. Patients were matched for time after transplantation and type of transplant. Anti-CD3-induced IL-10 production in MNCs isolated from patients with cGVHD (range/median: 26-650 pg/10(6) MNC; 400 pg/10(6) MNC) was significantly reduced compared to patients without cGVHD (646-2662 pg/10(6) MNC; 1314 pg/10(6) MNC; P < 0.05) or healthy controls (679-6361 pg/10(6) MNC; 3054 pg/10(6) MNC, P < 0.01). In vitro inhibition of IL-10 by an anti-IL-10 monoclonal antibody enhanced the release of IFN-gamma by anti-CD3-stimulated MNCs from 354 +/- 34 pg/10(6) MNCs to 899 +/- 61 pg/10(6) MNCs. Thus, low IL-10 production may cause high IFN-gamma release. In anti-CD3-activated MNCs obtained from patients with cGVHD IFN-gamma production was significantly increased (324-3331 pg/10(6) MNC; 1849 pg/10(6) MNC) compared to healthy donors (127-900 pg/10(6) MNC; 305 pg/10(6) MNC P < 0.01). In addition, median IFN-gamma release by anti-CD3-activated MNCs obtained from patients without cGVHD (464 pg/10(6) MNC) was about five-fold lower than in patients with cGVHD. In contrast to cytokine production, the differential leukocyte count (percentages of monocytes, T cells and CD4/CD8 ratio) was essentially the same both in patients with or without cGVHD. Thus, a different activation of Th-1 and Th-2 cells by anti-CD3 may be responsible for the deviant cytokine productions in patients with cGVHD. In conclusion, we observed significantly decreased IL-10 production in patinets with cGVHD and an increased median IFN-gamma secretion, which may contribute to the altered cytokine production after allogeneic BMT leading to cGVHD. Thus, supplementing IL-10 may become a new strategy for preventing cGVHD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9156246     DOI: 10.1038/sj.bmt.1700718

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  12 in total

1.  Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model.

Authors:  Florence Morin; Niloufar Kavian; Wioleta Marut; Christiane Chéreau; Olivier Cerles; Philippe Grange; Bernard Weill; Carole Nicco; Frédéric Batteux
Journal:  J Invest Dermatol       Date:  2015-05-04       Impact factor: 8.551

2.  Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease.

Authors:  Isao Tawara; Yaping Sun; Chen Liu; Tomomi Toubai; Evelyn Nieves; Rebecca Evers; Mariem Alrubaie; Nathan Mathewson; Hiroya Tamaki; Pavan Reddy
Journal:  J Leukoc Biol       Date:  2012-01-18       Impact factor: 4.962

3.  Increased Th17/Treg ratio in chronic liver GVHD.

Authors:  F Malard; C Bossard; E Brissot; P Chevallier; T Guillaume; J Delaunay; J-F Mosnier; P Moreau; M Grégoire; B Gaugler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

Review 4.  Chronic graft-versus-host disease: Pathogenesis and clinical management.

Authors:  José A Pérez-Simón; Ignacio Sánchez-Abarca; María Díez-Campelo; Dolores Caballero; Jesús San Miguel
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  New approaches for preventing and treating chronic graft-versus-host disease.

Authors:  Stephanie J Lee
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

6.  c-Rel is an essential transcription factor for the development of acute graft-versus-host disease in mice.

Authors:  Yu Yu; Dapeng Wang; Kane Kaosaard; Chen Liu; Jianing Fu; Kelley Haarberg; Claudio Anasetti; Amer A Beg; Xue-Zhong Yu
Journal:  Eur J Immunol       Date:  2013-07-04       Impact factor: 5.532

7.  Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease.

Authors:  Xiao Chen; Sanja Vodanovic-Jankovic; Bryon Johnson; Melissa Keller; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2007-08-10       Impact factor: 22.113

8.  c-Rel in GVHD biology: a missing link.

Authors:  Shoba Amarnath
Journal:  Eur J Immunol       Date:  2013-09       Impact factor: 5.532

9.  Cytokine gene polymorphism and graft-versus-host disease: a survey in Iranian bone marrow transplanted patients.

Authors:  Mohammad Reza Noori-Daloii; Nazanin Jalilian; Pantea Izadi; Maryam Sobhani; Zeinab Rabii-Gilani; Mir Saeed Yekaninejad
Journal:  Mol Biol Rep       Date:  2013-05-06       Impact factor: 2.316

10.  Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.

Authors:  Ahmad Khoder; Anushruti Sarvaria; Abdullah Alsuliman; Claude Chew; Takuya Sekine; Nichola Cooper; Stephan Mielke; Hugues de Lavallade; Muharrem Muftuoglu; Irina Fernandez Curbelo; Enli Liu; Paolo A Muraro; Amin Alousi; Kate Stringaris; Simrit Parmar; Nina Shah; Hila Shaim; Eric Yvon; Jeffrey Molldrem; Rayne Rouce; Richard Champlin; Ian McNiece; Claudia Mauri; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2014-07-22       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.